← All trials
NCT05743621
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Apr 30, 2027
- First posted
- Feb 24, 2023
- Last posted
- Mar 27, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cornell UniversityLead sponsor
- Cornell UniversityOverall official - principal investigator
- Sagimet Biosciences Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.